During the past decade, Alumis Central Site conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Alumis Central Site" are "Pharmacokinetics" (1 trials) and "Safety and Tolerability" (1 trials). Many other conditions were trialed in "Alumis Central Site" in a lesser frequency.

Most popular intervention types in "Alumis Central Site" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ESK-001" (1 trials), "Experimental drug: ESK-001" (1 trials), "Placebo" (1 trials) and "Rabeprazole" (1 trials). Other intervention names were less common.

The vast majority of trials in "Alumis Central Site" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Alumis Central Site". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Alumis Central Site, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Alumis Central Site, 2 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".